查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1243847

糖尿病黄斑部水肿的治疗的全球市场

Diabetic Macular Edema Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

糖尿病黄斑部水肿的治疗的全球市场2030年前将达到49亿美元

在COVID-19后改变的商务环境中，2022年41亿美元的糖尿病黄斑部水肿的治疗的全球市场，2030年前将达到49亿美元的规模，在2022年～2030年预计将以年复合成长率2.1％增长。本报告所分析之市场区隔之一的抗VEGF年复合成长率将记录2.4％，到分析期间结束时将达到24亿美元。考虑疫情后的復苏趋势，肾上腺皮质荷尔蒙剂市场领域今后8年的年复合成长率将修正为2％。

美国市场估算为12亿美元，中国则将以年复合成长率1.8％的速度成长。

美国的糖尿病黄斑部水肿的治疗市场在2022年估算为12亿美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为1.8％，2030年前将达到8亿5,580万美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以2.1％和1.4％的速度成长。在欧洲市场中，德国以年复合成长率1.7％成长。

调查对像企业范例

  • Acucela Inc.
  • Aerie Pharmaceuticals, Inc.
  • Aerpio Pharmaceuticals
  • Antisense Therapeutics Limited
  • Araim Pharmaceuticals, Inc.
  • BCN Peptides S.A.
  • Biomar Microbial Technologies
  • Charlesson LLC
  • Coherus BioSciences

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP13146

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Diabetic Macular Edema Treatment Market to Reach $4.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Diabetic Macular Edema Treatment estimated at US$4.1 Billion in the year 2022, is projected to reach a revised size of US$4.9 Billion by 2030, growing at aCAGR of 2.1% over the period 2022-2030. Anti-VEGF, one of the segments analyzed in the report, is projected to record 2.4% CAGR and reach US$2.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroid segment is readjusted to a revised 2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 1.8% CAGR

The Diabetic Macular Edema Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$855.8 Million by the year 2030 trailing a CAGR of 1.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 1.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Select Competitors (Total 38 Featured) -

  • Acucela Inc.
  • Aerie Pharmaceuticals, Inc.
  • Aerpio Pharmaceuticals
  • Antisense Therapeutics Limited
  • Araim Pharmaceuticals, Inc.
  • BCN Peptides S.A.
  • Biomar Microbial Technologies
  • Charlesson LLC
  • Coherus BioSciences

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Diabetic Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Corticosteroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Diabetic Macular Edema Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • JAPAN
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • CHINA
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: China 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • EUROPE
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • FRANCE
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: France 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • GERMANY
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Rest of Europe 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Asia-Pacific 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Rest of World 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030

IV. COMPETITION